14-02-2012: Oxford BioMedica announced that Andrew Wood, Chief Financial Officer, has stepped down from the Board of Oxford BioMedica. Tim Watts has been appointed to the Board as Chief Financial Officer and Company Secretary of Oxford BioMedica with immediate effect. Andrew will continue as an employee of the Company for the time being to ensure the smooth transition of the role.
Tim is a senior financial executive with over 30 years’ experience in leading multinational and entrepreneurial businesses. He was most recently Chief Financial Officer at Archimedes Pharma Ltd., an international specialty pharmaceutical company. Tim qualified as a chartered accountant, beginning his career with Coopers & Lybrand before moving to H J Heinz, the food producer. In 1985 Tim joined ICI, initially in the corporate headquarters and from 1990 in the pharmaceuticals division, eventually rising to be Finance Director of the Zeneca Pharmaceuticals business. Following the merger of Astra and Zeneca, Tim became Group Financial Controller of AstraZeneca PLC in 2001. In 2007 he left AstraZeneca to become Chief Financial Officer at Archimedes Pharma. Tim has a proven track record in the industry, including managing corporate transactions, M&A activity, fundraising and strategic implementation.
Oxford BioMedica announced the appointment of Martin Diggle as a non-Executive Director of the Company, effective as of 4 October 2012.Martin is a founder of Vulpes Investment Management, a Cayman Fund Manager which currently manages five funds including the Vulpes Life Sciences Fund; Oxfor ... more
Oxford BioMedica plc announced that its partners at Cardiff University, Wales (UK) have initiated a Phase II trial to assess the safety and immunological activity of TroVax®, a therapeutic vaccine developed by Oxford BioMedica, in patients with inoperable metastatic colorectal cancer (CRC). ... more
Oxford BioMedica plc announces that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to manufacture bulk drug material for Investigational Medicinal Products (IMPs) at the Company’s specialist manufacturing facility in Cowley, Oxford. This re ... more
Oxford BioMedica is a biopharmaceutical company specializing in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. The Company has a platform of gene delivery technologies, whi ... more